We have added the second short review of a recent study: Improvement in overall survival with carfilzomib, lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. This is the second of three new, short studies published over the next month.
Independent commentary is provided by Associate Professor Cindy Lee, the clinical co-lead in the myeloma program at Royal Adelaide Hospital and The Queen Elizabeth Hospital, South Australia.
Please login below to download this issue (PDF)